ID   PA24A_HUMAN             Reviewed;         749 AA.
AC   P47712; B1AKG4; Q29R80;
DT   01-FEB-1996, integrated into UniProtKB/Swiss-Prot.
DT   11-JAN-2011, sequence version 2.
DT   10-MAY-2017, entry version 182.
DE   RecName: Full=Cytosolic phospholipase A2;
DE            Short=cPLA2;
DE   AltName: Full=Phospholipase A2 group IVA;
DE   Includes:
DE     RecName: Full=Phospholipase A2;
DE              EC=3.1.1.4;
DE     AltName: Full=Phosphatidylcholine 2-acylhydrolase;
DE   Includes:
DE     RecName: Full=Lysophospholipase;
DE              EC=3.1.1.5;
GN   Name=PLA2G4A; Synonyms=CPLA2, PLA2G4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], PARTIAL PROTEIN SEQUENCE, AND VARIANT
RP   LYS-651.
RX   PubMed=1904318; DOI=10.1016/0092-8674(91)90556-E;
RA   Clark J.D., Lin L.-L., Kriz R.W., Ramesha C.S., Sultzman L.A.,
RA   Lin A.Y., Milona N., Knopf J.L.;
RT   "A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-
RT   dependent translocation domain with homology to PKC and GAP.";
RL   Cell 65:1043-1051(1991).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND VARIANT LYS-651.
RX   PubMed=1869522;
RA   Sharp J., White D., Chiou G., Goodson T., Gamboa G., McClure D.,
RA   Burgett S., Hoskins J., Skatrud P., Sportsman J., Becker G., Kang L.,
RA   Roberts E., Kramer R.;
RT   "Molecular cloning and expression of human Ca(2+)-sensitive cytosolic
RT   phospholipase A2.";
RL   J. Biol. Chem. 266:14850-14853(1991).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS ILE-224 AND LYS-651.
RG   NIEHS SNPs program;
RL   Submitted (FEB-2004) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA], AND VARIANT LYS-651.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   MUTAGENESIS OF SER-505, AND PHOSPHORYLATION AT SER-505.
RX   PubMed=8381049; DOI=10.1016/0092-8674(93)90666-E;
RA   Lin L.-L., Wartmann M., Lin A.Y., Knopf J.L., Seth A., Davis R.J.;
RT   "cPLA2 is phosphorylated and activated by MAP kinase.";
RL   Cell 72:269-278(1993).
RN   [7]
RP   ACTIVE SITE, MUTAGENESIS OF CYS-139; CYS-141; CYS-151; SER-195;
RP   SER-215; CYS-220; SER-228; CYS-324; CYS-331; SER-577; CYS-620; CYS-634
RP   AND CYS-726, AND BIOPHYSICOCHEMICAL PROPERTIES.
RX   PubMed=8083230;
RA   Sharp J.D., Pickard R.T., Chiou X.G., Manetta J.V., Kovacevic S.,
RA   Miller J.R., Varshavsky A.D., Roberts E.F., Strifler B.A., Brems D.N.,
RA   Kramer R.M.;
RT   "Serine 228 is essential for catalytic activities of 85-kDa cytosolic
RT   phospholipase A2.";
RL   J. Biol. Chem. 269:23250-23254(1994).
RN   [8]
RP   CATALYTIC ACTIVITY, SUBCELLULAR LOCATION, ACTIVE SITE, AND MUTAGENESIS
RP   OF SER-228.
RX   PubMed=8619991; DOI=10.1021/bi952541k;
RA   Huang Z., Payette P., Abdullah K., Cromlish W.A., Kennedy B.P.;
RT   "Functional identification of the active-site nucleophile of the human
RT   85-kDa cytosolic phospholipase A2.";
RL   Biochemistry 35:3712-3721(1996).
RN   [9]
RP   ACTIVE SITE, CATALYTIC ACTIVITY, AND MUTAGENESIS OF ARG-200; SER-228
RP   AND ASP-549.
RX   PubMed=8702602; DOI=10.1074/jbc.271.32.19225;
RA   Pickard R.T., Chiou X.G., Strifler B.A., DeFelippis M.R., Hyslop P.A.,
RA   Tebbe A.L., Yee Y.K., Reynolds L.J., Dennis E.A., Kramer R.M.,
RA   Sharp J.D.;
RT   "Identification of essential residues for the catalytic function of
RT   85-kDa cytosolic phospholipase A2. Probing the role of histidine,
RT   aspartic acid, cysteine, and arginine.";
RL   J. Biol. Chem. 271:19225-19231(1996).
RN   [10]
RP   PHOSPHORYLATION AT SER-505 AND SER-727.
RX   PubMed=9468497; DOI=10.1074/jbc.273.8.4449;
RA   Boersch-Haubold A.G., Bartoli F., Asselin J., Dudler T., Kramer R.M.,
RA   Apitz-Castro R., Watson S.P., Gelb M.H.;
RT   "Identification of the phosphorylation sites of cytosolic
RT   phospholipase A2 in agonist-stimulated human platelets and HeLa
RT   cells.";
RL   J. Biol. Chem. 273:4449-4458(1998).
RN   [11]
RP   INTERACTION WITH KAT5.
RX   PubMed=11416127; DOI=10.1128/MCB.21.14.4470-4481.2001;
RA   Sheridan A.M., Force T., Yoon H.J., O'Leary E., Choukroun G.,
RA   Taheri M.R., Bonventre J.V.;
RT   "PLIP, a novel splice variant of Tip60, interacts with group IV
RT   cytosolic phospholipase A(2), induces apoptosis, and potentiates
RT   prostaglandin production.";
RL   Mol. Cell. Biol. 21:4470-4481(2001).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,
RA   Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in
RT   signaling networks.";
RL   Cell 127:635-648(2006).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-729, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=16964243; DOI=10.1038/nbt1240;
RA   Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.;
RT   "A probability-based approach for high-throughput protein
RT   phosphorylation analysis and site localization.";
RL   Nat. Biotechnol. 24:1285-1292(2006).
RN   [14]
RP   INVOLVEMENT IN PHOSPHOLIPASE A2 DEFICIENCY, AND VARIANTS PRO-111;
RP   HIS-485 AND LYS-651.
RX   PubMed=18451993; DOI=10.1172/JCI30473;
RA   Adler D.H., Cogan J.D., Phillips J.A., Schnetz-Boutaud N., Milne G.L.,
RA   Iverson T., Stein J.A., Brenner D.A., Morrow J.D., Boutaud O.,
RA   Oates J.A.;
RT   "Inherited human cPLA(2alpha) deficiency is associated with impaired
RT   eicosanoid biosynthesis, small intestinal ulceration, and platelet
RT   dysfunction.";
RL   J. Clin. Invest. 118:2121-2131(2008).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-268; SER-437; SER-727
RP   AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-268; SER-437 AND
RP   SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S.,
RA   Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full
RT   phosphorylation site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-437, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J.,
RA   Johansen P.T., Kratchmarova I., Kassem M., Mann M., Olsen J.V.,
RA   Blagoev B.;
RT   "System-wide temporal characterization of the proteome and
RT   phosphoproteome of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-2; THR-268; SER-435;
RP   SER-437; SER-727 AND SER-729, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 16-141 IN COMPLEX WITH
RP   CALCIUM IONS, AND DOMAIN.
RX   PubMed=9430701; DOI=10.1074/jbc.273.3.1596;
RA   Perisic O., Fong S., Lynch D.E., Bycroft M., Williams R.L.;
RT   "Crystal structure of a calcium-phospholipid binding domain from
RT   cytosolic phospholipase A2.";
RL   J. Biol. Chem. 273:1596-1604(1998).
RN   [22]
RP   STRUCTURE BY NMR OF 1-138 IN COMPLEX WITH CALCIUM IONS, DOMAIN, AND
RP   SUBCELLULAR LOCATION.
RX   PubMed=9665851; DOI=10.1006/jmbi.1998.1874;
RA   Xu G.-Y., McDonagh T., Yu H.-A., Nalefski E.A., Clark J.D.,
RA   Cumming D.A.;
RT   "Solution structure and membrane interactions of the C2 domain of
RT   cytosolic phospholipase A2.";
RL   J. Mol. Biol. 280:485-500(1998).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) IN COMPLEX WITH CALCIUM IONS,
RP   AND ACTIVE SITE.
RX   PubMed=10319815; DOI=10.1016/S0092-8674(00)80744-8;
RA   Dessen A., Tang J., Schmidt H., Stahl M., Clark J.D., Seehra J.,
RA   Somers W.S.;
RT   "Crystal structure of human cytosolic phospholipase A2 reveals a novel
RT   topology and catalytic mechanism.";
RL   Cell 97:349-360(1999).
RN   [24]
RP   VARIANT [LARGE SCALE ANALYSIS] GLN-442.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
CC   -!- FUNCTION: Selectively hydrolyzes arachidonyl phospholipids in the
CC       sn-2 position releasing arachidonic acid. Together with its
CC       lysophospholipid activity, it is implicated in the initiation of
CC       the inflammatory response.
CC   -!- CATALYTIC ACTIVITY: Phosphatidylcholine + H(2)O = 1-
CC       acylglycerophosphocholine + a carboxylate.
CC   -!- CATALYTIC ACTIVITY: 2-lysophosphatidylcholine + H(2)O =
CC       glycerophosphocholine + a carboxylate.
CC   -!- ENZYME REGULATION: Stimulated by agonists such as ATP, EGF,
CC       thrombin and bradykinin as well as by cytosolic Ca(2+).
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         Vmax=2.7 umol/min/mg enzyme for the phospholipase A2 reaction
CC         {ECO:0000269|PubMed:8083230};
CC         Vmax=4.6 umol/min/mg enzyme for the lysophosphatase reaction
CC         {ECO:0000269|PubMed:8083230};
CC   -!- SUBUNIT: Interacts with KAT5. {ECO:0000269|PubMed:10319815,
CC       ECO:0000269|PubMed:11416127, ECO:0000269|PubMed:9430701,
CC       ECO:0000269|PubMed:9665851}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasmic vesicle.
CC       Note=Translocates to membrane vesicles in a calcium-dependent
CC       fashion.
CC   -!- TISSUE SPECIFICITY: Expressed in various tissues such as
CC       macrophages, platelets, neutrophils, fibroblasts and lung
CC       endothelium.
CC   -!- DOMAIN: The N-terminal C2 domain associates with lipid membranes
CC       upon calcium binding. It modulates enzyme activity by presenting
CC       the active site to its substrate in response to elevations of
CC       cytosolic Ca(2+). {ECO:0000269|PubMed:9430701,
CC       ECO:0000269|PubMed:9665851}.
CC   -!- PTM: Activated by phosphorylation at both Ser-505 and Ser-727.
CC       {ECO:0000269|PubMed:8381049, ECO:0000269|PubMed:9468497}.
CC   -!- DISEASE: Note=PLA2G4A mutations resulting in phospholipase A2
CC       deficiency have been found in a patient affected by recurrent
CC       episodes of multiple complicated ulcers of the small intestine,
CC       not due to cyclooxygenase inhibitors use. Disease features also
CC       include platelet dysfunction, and globally decreased eicosanoid
CC       synthesis (PubMed:18451993). {ECO:0000269|PubMed:18451993}.
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/pla2g4a/";
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology
CC       and Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/PLA2G4AID41733ch1q31.html";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M72393; AAB00789.1; -; mRNA.
DR   EMBL; M68874; AAA60105.1; -; mRNA.
DR   EMBL; AY552098; AAS45712.1; -; Genomic_DNA.
DR   EMBL; AL022147; CAB42689.2; -; Genomic_DNA.
DR   EMBL; AL049797; CAI22252.1; -; Genomic_DNA.
DR   EMBL; AL022147; CAI22252.1; JOINED; Genomic_DNA.
DR   EMBL; BC114340; AAI14341.1; -; mRNA.
DR   CCDS; CCDS1372.1; -.
DR   PIR; A39329; A39329.
DR   RefSeq; NP_001298122.1; NM_001311193.1.
DR   RefSeq; NP_077734.1; NM_024420.2.
DR   RefSeq; XP_011507944.1; XM_011509642.2.
DR   UniGene; Hs.497200; -.
DR   PDB; 1BCI; NMR; -; A=1-138.
DR   PDB; 1CJY; X-ray; 2.50 A; A/B=1-749.
DR   PDB; 1RLW; X-ray; 2.40 A; A=17-141.
DR   PDBsum; 1BCI; -.
DR   PDBsum; 1CJY; -.
DR   PDBsum; 1RLW; -.
DR   ProteinModelPortal; P47712; -.
DR   SMR; P47712; -.
DR   BioGrid; 111338; 30.
DR   DIP; DIP-40991N; -.
DR   IntAct; P47712; 5.
DR   MINT; MINT-118843; -.
DR   STRING; 9606.ENSP00000356436; -.
DR   BindingDB; P47712; -.
DR   ChEMBL; CHEMBL3816; -.
DR   DrugBank; DB00041; Aldesleukin.
DR   DrugBank; DB00411; Carbachol.
DR   DrugBank; DB00578; Carbenicillin.
DR   DrugBank; DB05029; Duramycin.
DR   DrugBank; DB00445; Epirubicin.
DR   DrugBank; DB04827; Ethyl carbamate.
DR   DrugBank; DB00591; Fluocinolone Acetonide.
DR   DrugBank; DB00588; Fluticasone Propionate.
DR   DrugBank; DB04552; Niflumic Acid.
DR   DrugBank; DB01083; Orlistat.
DR   DrugBank; DB01103; Quinacrine.
DR   DrugBank; DB00086; Streptokinase.
DR   DrugBank; DB04786; Suramin.
DR   GuidetoPHARMACOLOGY; 1424; -.
DR   SwissLipids; SLP:000000565; -.
DR   iPTMnet; P47712; -.
DR   PhosphoSitePlus; P47712; -.
DR   BioMuta; PLA2G4A; -.
DR   DMDM; 317373312; -.
DR   EPD; P47712; -.
DR   MaxQB; P47712; -.
DR   PaxDb; P47712; -.
DR   PeptideAtlas; P47712; -.
DR   PRIDE; P47712; -.
DR   Ensembl; ENST00000367466; ENSP00000356436; ENSG00000116711.
DR   GeneID; 5321; -.
DR   KEGG; hsa:5321; -.
DR   UCSC; uc001gsc.4; human.
DR   CTD; 5321; -.
DR   DisGeNET; 5321; -.
DR   GeneCards; PLA2G4A; -.
DR   HGNC; HGNC:9035; PLA2G4A.
DR   HPA; CAB010050; -.
DR   HPA; HPA050062; -.
DR   HPA; HPA054206; -.
DR   MalaCards; PLA2G4A; -.
DR   MIM; 600522; gene.
DR   neXtProt; NX_P47712; -.
DR   OpenTargets; ENSG00000116711; -.
DR   PharmGKB; PA271; -.
DR   eggNOG; KOG1012; Eukaryota.
DR   eggNOG; KOG1325; Eukaryota.
DR   eggNOG; ENOG410XR72; LUCA.
DR   GeneTree; ENSGT00550000074489; -.
DR   HOGENOM; HOG000115420; -.
DR   HOVERGEN; HBG053479; -.
DR   InParanoid; P47712; -.
DR   KO; K16342; -.
DR   OMA; RFSMALC; -.
DR   OrthoDB; EOG091G0276; -.
DR   PhylomeDB; P47712; -.
DR   TreeFam; TF325228; -.
DR   BioCyc; MetaCyc:HS04039-MONOMER; -.
DR   BRENDA; 3.1.1.4; 2681.
DR   Reactome; R-HSA-111995; phospho-PLA2 pathway.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482798; Acyl chain remodeling of CL.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   Reactome; R-HSA-1482925; Acyl chain remodelling of PG.
DR   Reactome; R-HSA-1483115; Hydrolysis of LPC.
DR   Reactome; R-HSA-1483166; Synthesis of PA.
DR   Reactome; R-HSA-2142753; Arachidonic acid metabolism.
DR   Reactome; R-HSA-418592; ADP signalling through P2Y purinoceptor 1.
DR   Reactome; R-HSA-432142; Platelet sensitization by LDL.
DR   Reactome; R-HSA-6811436; COPI-independent Golgi-to-ER retrograde traffic.
DR   SIGNOR; P47712; -.
DR   EvolutionaryTrace; P47712; -.
DR   GeneWiki; PLA2G4A; -.
DR   GenomeRNAi; 5321; -.
DR   PMAP-CutDB; P47712; -.
DR   PRO; PR:P47712; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000116711; -.
DR   CleanEx; HS_PLA2G4A; -.
DR   Genevisible; P47712; HS.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005811; C:lipid particle; IDA:HPA.
DR   GO; GO:0005743; C:mitochondrial inner membrane; TAS:Reactome.
DR   GO; GO:0005509; F:calcium ion binding; IDA:UniProtKB.
DR   GO; GO:0047498; F:calcium-dependent phospholipase A2 activity; EXP:Reactome.
DR   GO; GO:0005544; F:calcium-dependent phospholipid binding; IDA:UniProtKB.
DR   GO; GO:0004622; F:lysophospholipase activity; TAS:Reactome.
DR   GO; GO:0008970; F:phosphatidylcholine 1-acylhydrolase activity; TAS:Reactome.
DR   GO; GO:0004623; F:phospholipase A2 activity; IDA:UniProtKB.
DR   GO; GO:0019369; P:arachidonic acid metabolic process; TAS:Reactome.
DR   GO; GO:0050482; P:arachidonic acid secretion; IEA:Ensembl.
DR   GO; GO:0035965; P:cardiolipin acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0071236; P:cellular response to antibiotic; IEA:Ensembl.
DR   GO; GO:0046456; P:icosanoid biosynthetic process; IEA:Ensembl.
DR   GO; GO:0006690; P:icosanoid metabolic process; NAS:UniProtKB.
DR   GO; GO:0006654; P:phosphatidic acid biosynthetic process; TAS:Reactome.
DR   GO; GO:0036151; P:phosphatidylcholine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036152; P:phosphatidylethanolamine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036148; P:phosphatidylglycerol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036149; P:phosphatidylinositol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0036150; P:phosphatidylserine acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:0009395; P:phospholipid catabolic process; IEA:InterPro.
DR   GO; GO:0006644; P:phospholipid metabolic process; TAS:Reactome.
DR   GO; GO:0006663; P:platelet activating factor biosynthetic process; NAS:UniProtKB.
DR   GO; GO:0042127; P:regulation of cell proliferation; IEA:Ensembl.
DR   Gene3D; 2.60.40.150; -; 1.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR002642; LysoPLipase_cat_dom.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF01735; PLA2_B; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00022; PLAc; 1.
DR   SUPFAM; SSF49562; SSF49562; 1.
DR   SUPFAM; SSF52151; SSF52151; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS51210; PLA2C; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Calcium; Complete proteome; Cytoplasm;
KW   Cytoplasmic vesicle; Direct protein sequencing; Disease mutation;
KW   Hydrolase; Lipid degradation; Lipid metabolism; Metal-binding;
KW   Phosphoprotein; Polymorphism; Reference proteome.
FT   CHAIN         1    749       Cytosolic phospholipase A2.
FT                                /FTId=PRO_0000187262.
FT   DOMAIN        5    106       C2. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00041}.
FT   DOMAIN      140    740       PLA2c. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00555}.
FT   REGION        1    178       Phospholipid binding. {ECO:0000305}.
FT   ACT_SITE    228    228       Nucleophile.
FT   ACT_SITE    549    549       Proton acceptor.
FT   METAL        40     40       Calcium 1.
FT   METAL        40     40       Calcium 2.
FT   METAL        41     41       Calcium 1; via carbonyl oxygen.
FT   METAL        43     43       Calcium 1.
FT   METAL        43     43       Calcium 2.
FT   METAL        65     65       Calcium 1.
FT   METAL        93     93       Calcium 2.
FT   METAL        94     94       Calcium 2; via carbonyl oxygen.
FT   METAL        95     95       Calcium 2.
FT   MOD_RES       2      2       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     268    268       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     434    434       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P50393}.
FT   MOD_RES     435    435       Phosphoserine.
FT                                {ECO:0000244|PubMed:23186163}.
FT   MOD_RES     437    437       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:21406692,
FT                                ECO:0000244|PubMed:23186163}.
FT   MOD_RES     505    505       Phosphoserine; by MAPK.
FT                                {ECO:0000269|PubMed:8381049,
FT                                ECO:0000269|PubMed:9468497}.
FT   MOD_RES     515    515       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P50393}.
FT   MOD_RES     727    727       Phosphoserine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:23186163,
FT                                ECO:0000269|PubMed:9468497}.
FT   MOD_RES     729    729       Phosphoserine.
FT                                {ECO:0000244|PubMed:16964243,
FT                                ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:20068231,
FT                                ECO:0000244|PubMed:23186163}.
FT   VARIANT     103    103       G -> R (in dbSNP:rs28395828).
FT                                /FTId=VAR_029276.
FT   VARIANT     111    111       S -> P (probable disease-associated
FT                                mutation found in a compound heterozygote
FT                                affected by phospholipase A2 deficiency
FT                                also carrying H-485; dbSNP:rs121434634).
FT                                {ECO:0000269|PubMed:18451993}.
FT                                /FTId=VAR_070778.
FT   VARIANT     224    224       V -> I (in dbSNP:rs12720588).
FT                                {ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018760.
FT   VARIANT     442    442       H -> Q (in a breast cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035826.
FT   VARIANT     485    485       R -> H (probable disease-associated
FT                                mutation found in a compound heterozygote
FT                                affected by phospholipase A2 deficiency
FT                                also carrying P-111; dbSNP:rs121434635).
FT                                {ECO:0000269|PubMed:18451993}.
FT                                /FTId=VAR_070779.
FT   VARIANT     637    637       I -> V (in dbSNP:rs28395831).
FT                                /FTId=VAR_062128.
FT   VARIANT     651    651       R -> K (in dbSNP:rs2307198).
FT                                {ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18451993,
FT                                ECO:0000269|PubMed:1869522,
FT                                ECO:0000269|PubMed:1904318,
FT                                ECO:0000269|Ref.3}.
FT                                /FTId=VAR_018424.
FT   MUTAGEN     139    139       C->A: No effect on phospholipase
FT                                activity; when associated with A-141 and
FT                                A-151. {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     141    141       C->A: No effect on phospholipase
FT                                activity; when associated with A-139 and
FT                                A-151. {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     151    151       C->A: No effect on phospholipase
FT                                activity; when associated with A-139 and
FT                                A-141. {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     195    195       S->A: 5-fold reduced phospholipase and
FT                                lysophosphatase activities. 100-fold
FT                                reduced phospholipase and lysophosphatase
FT                                activities; when associated with A-577.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     200    200       R->A,H: Abolishes phospholipase activity.
FT                                {ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     200    200       R->K: Reduces phospholipase activity 200-
FT                                fold. {ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     215    215       S->A: No effect on phospholipase or
FT                                lysophosphatase activity.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     220    220       C->A: No effect on phospholipase
FT                                activity. {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     228    228       S->A,C,T: Abolishes both phospholipase
FT                                and lysophosphatase activities.
FT                                {ECO:0000269|PubMed:8083230,
FT                                ECO:0000269|PubMed:8619991,
FT                                ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     324    324       C->A: No effect on phospholipase
FT                                activity; when associated with A-331.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     331    331       C->A: No effect on phospholipase
FT                                activity; when associated with A-324.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     505    505       S->A: Decreases agonist-stimulated
FT                                release of arachidonic acid.
FT                                {ECO:0000269|PubMed:8381049}.
FT   MUTAGEN     549    549       D->A: Abolishes phospholipiase activity.
FT                                {ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     549    549       D->E: Reduces phospholipiase activity
FT                                2000-fold. {ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     549    549       D->N: Reduces phospholipiase activity
FT                                300-fold. {ECO:0000269|PubMed:8702602}.
FT   MUTAGEN     577    577       S->A: 7-fold reduced phospholipase and
FT                                lysophosphatase activities. 100-fold
FT                                reduced phospholipase and lysophosphatase
FT                                activities; when associated with A-195.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     620    620       C->A: No effect on phospholipase
FT                                activity; when associated with A-634.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     634    634       C->A: No effect on phospholipase
FT                                activity; when associated with A-620.
FT                                {ECO:0000269|PubMed:8083230}.
FT   MUTAGEN     726    726       C->A: No effect on phospholipase
FT                                activity. {ECO:0000269|PubMed:8083230}.
FT   STRAND       18     29       {ECO:0000244|PDB:1RLW}.
FT   HELIX        34     39       {ECO:0000244|PDB:1RLW}.
FT   STRAND       44     49       {ECO:0000244|PDB:1RLW}.
FT   STRAND       51     54       {ECO:0000244|PDB:1BCI}.
FT   STRAND       57     60       {ECO:0000244|PDB:1BCI}.
FT   STRAND       70     79       {ECO:0000244|PDB:1RLW}.
FT   STRAND       86     93       {ECO:0000244|PDB:1RLW}.
FT   STRAND       96     98       {ECO:0000244|PDB:1CJY}.
FT   STRAND      100    108       {ECO:0000244|PDB:1RLW}.
FT   HELIX       109    111       {ECO:0000244|PDB:1RLW}.
FT   STRAND      117    124       {ECO:0000244|PDB:1RLW}.
FT   TURN        125    127       {ECO:0000244|PDB:1RLW}.
FT   STRAND      128    137       {ECO:0000244|PDB:1RLW}.
FT   STRAND      143    146       {ECO:0000244|PDB:1CJY}.
FT   HELIX       152    177       {ECO:0000244|PDB:1CJY}.
FT   HELIX       179    181       {ECO:0000244|PDB:1CJY}.
FT   STRAND      190    194       {ECO:0000244|PDB:1CJY}.
FT   HELIX       198    214       {ECO:0000244|PDB:1CJY}.
FT   HELIX       218    220       {ECO:0000244|PDB:1CJY}.
FT   STRAND      221    226       {ECO:0000244|PDB:1CJY}.
FT   HELIX       228    239       {ECO:0000244|PDB:1CJY}.
FT   TURN        241    245       {ECO:0000244|PDB:1CJY}.
FT   HELIX       248    260       {ECO:0000244|PDB:1CJY}.
FT   HELIX       263    266       {ECO:0000244|PDB:1CJY}.
FT   HELIX       269    284       {ECO:0000244|PDB:1CJY}.
FT   HELIX       291    304       {ECO:0000244|PDB:1CJY}.
FT   HELIX       305    307       {ECO:0000244|PDB:1CJY}.
FT   HELIX       313    318       {ECO:0000244|PDB:1CJY}.
FT   TURN        319    321       {ECO:0000244|PDB:1CJY}.
FT   STRAND      326    333       {ECO:0000244|PDB:1CJY}.
FT   HELIX       341    343       {ECO:0000244|PDB:1CJY}.
FT   STRAND      344    349       {ECO:0000244|PDB:1CJY}.
FT   STRAND      354    356       {ECO:0000244|PDB:1CJY}.
FT   TURN        357    360       {ECO:0000244|PDB:1CJY}.
FT   STRAND      361    363       {ECO:0000244|PDB:1CJY}.
FT   HELIX       365    367       {ECO:0000244|PDB:1CJY}.
FT   STRAND      370    373       {ECO:0000244|PDB:1CJY}.
FT   STRAND      376    379       {ECO:0000244|PDB:1CJY}.
FT   HELIX       386    393       {ECO:0000244|PDB:1CJY}.
FT   HELIX       396    399       {ECO:0000244|PDB:1CJY}.
FT   HELIX       401    404       {ECO:0000244|PDB:1CJY}.
FT   HELIX       417    423       {ECO:0000244|PDB:1CJY}.
FT   HELIX       426    429       {ECO:0000244|PDB:1CJY}.
FT   HELIX       463    476       {ECO:0000244|PDB:1CJY}.
FT   STRAND      488    490       {ECO:0000244|PDB:1CJY}.
FT   TURN        492    495       {ECO:0000244|PDB:1CJY}.
FT   STRAND      543    548       {ECO:0000244|PDB:1CJY}.
FT   HELIX       550    552       {ECO:0000244|PDB:1CJY}.
FT   HELIX       558    561       {ECO:0000244|PDB:1CJY}.
FT   HELIX       564    566       {ECO:0000244|PDB:1CJY}.
FT   STRAND      570    575       {ECO:0000244|PDB:1CJY}.
FT   HELIX       588    599       {ECO:0000244|PDB:1CJY}.
FT   HELIX       611    615       {ECO:0000244|PDB:1CJY}.
FT   STRAND      619    623       {ECO:0000244|PDB:1CJY}.
FT   STRAND      636    641       {ECO:0000244|PDB:1CJY}.
FT   HELIX       646    648       {ECO:0000244|PDB:1CJY}.
FT   STRAND      650    652       {ECO:0000244|PDB:1CJY}.
FT   HELIX       660    666       {ECO:0000244|PDB:1CJY}.
FT   STRAND      670    672       {ECO:0000244|PDB:1CJY}.
FT   HELIX       687    702       {ECO:0000244|PDB:1CJY}.
FT   HELIX       705    718       {ECO:0000244|PDB:1CJY}.
SQ   SEQUENCE   749 AA;  85239 MW;  EE71CA0EBE617856 CRC64;
     MSFIDPYQHI IVEHQYSHKF TVVVLRATKV TKGAFGDMLD TPDPYVELFI STTPDSRKRT
     RHFNNDINPV WNETFEFILD PNQENVLEIT LMDANYVMDE TLGTATFTVS SMKVGEKKEV
     PFIFNQVTEM VLEMSLEVCS CPDLRFSMAL CDQEKTFRQQ RKEHIRESMK KLLGPKNSEG
     LHSARDVPVV AILGSGGGFR AMVGFSGVMK ALYESGILDC ATYVAGLSGS TWYMSTLYSH
     PDFPEKGPEE INEELMKNVS HNPLLLLTPQ KVKRYVESLW KKKSSGQPVT FTDIFGMLIG
     ETLIHNRMNT TLSSLKEKVN TAQCPLPLFT CLHVKPDVSE LMFADWVEFS PYEIGMAKYG
     TFMAPDLFGS KFFMGTVVKK YEENPLHFLM GVWGSAFSIL FNRVLGVSGS QSRGSTMEEE
     LENITTKHIV SNDSSDSDDE SHEPKGTENE DAGSDYQSDN QASWIHRMIM ALVSDSALFN
     TREGRAGKVH NFMLGLNLNT SYPLSPLSDF ATQDSFDDDE LDAAVADPDE FERIYEPLDV
     KSKKIHVVDS GLTFNLPYPL ILRPQRGVDL IISFDFSARP SDSSPPFKEL LLAEKWAKMN
     KLPFPKIDPY VFDREGLKEC YVFKPKNPDM EKDCPTIIHF VLANINFRKY RAPGVPRETE
     EEKEIADFDI FDDPESPFST FNFQYPNQAF KRLHDLMHFN TLNNIDVIKE AMVESIEYRR
     QNPSRCSVSL SNVEARRFFN KEFLSKPKA
//
